We are working to reduce carbon emissions across our supply chain. We work across all three of our freight transportation modes - road, ocean and air - to that end. Supply reliability and transport efficiency are primary objectives. We focus on full truck loads and double stacking of pallets where possible and partner with our freight partners to move from dedicated containers to sharing capacity with other companies to better utilize space across the industry. Full truck loads are considered the most efficient mode of transit.

In 2023, road and ocean represented 81% of all our transport. As timely access to medicine is the priority, there are exceptions when speed is of the essence and air transport may be required, representing 19% of our transport in 2023. As part of protecting supply reliability and reducing GHG emissions, we are looking into railway as another mode of transport. Further, we are looking at more sustainable packaging solutions to prepare our products for shipments.

As Viatris, we are compliant with the AMRIA Antibiotic Manufacturing Standard for our own operations and committed to implementing it across our external supply chain. All applicable Viatris manufacturing locations with antibiotic production have been internally assessed and adhere to the AMRIA Antibiotic Manufacturing Standard, including meeting the PNEC (RQ<1) as calculated by mass balance.

Milestone Certification for Reducing the Risk of AMR in Manufacturing

Our manufacturing for all dosages of the antibiotic Ciprofloxacin at our facility in Aurangabad, India, became the first at Viatris to receive British Standards Institute (BSI) Certification under the Antibiotic Manufacturing Standard. It is also the only site in India to hold this certification.¹ The BSI Kitemark™ for minimized risk of antimicrobial resistance provides independent, third-party assurance and demonstrates that antibiotic residue emissions from solid and liquid waste streams are effectively controlled during manufacturing.

1 as of February 2024